Mainstream

ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend

ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend

Post Contentrmd, rsmdfRead More

You might also be interested in reading Debunking the 'Binance manipulator' theory: 3 reasons why the allegation falls short.

August 1, 2025
In Mainstream